Patent · US Active

HBV treatment

US9080174B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

Benitec Biopharma Limited · AU

Inventors

Michael Wayne Graham · Jindalee, AU
Peter French · Sydney, AU
York YuanYuan Zhu · Palo Alto, US
YiXiang Lu · Jiangshui, CN
Tiejun Li · Beijing, CN
YunCheng Sun · Nantong, CN
XiaoJun Tang · Nantong, CN
Li Shan · Laval, CA

Key dates

Filing date	Oct 27, 2011
Grant date	Jul 14, 2015
Priority date	—
Expiry date	Oct 27, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/531
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.